ReviewCells2026
The Crosstalk Between Metabolic Reprogramming and Histone Methylation in Tumor Immunity and Immunotherapy.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Histone methylation regulates chromatin structure and gene expression, whereas tumor metabolism provides bioenergetic and biosynthetic inputs. These processes are bidirectionally linked: S-adenosylmethionine supplies methyl groups for histone methyltransferases, α-ketoglutarate(α-KG) supports JmjC-domain demethylases, and D-2-hydroxyglutarate (D-2HG) can inhibit α-KG-dependent dioxygenases. Conversely, histone methylation can regulate metabolic gene expression, as illustrated by KMT2D-dependent enhancer remodeling and glycolytic gene expression in melanoma models. Lactate regulates chromatin through histone lactylation, a modification distinct from histone methylation; where the two intersect, as in the retinoblastoma H3K18la-SUZ12/PRC2-H3K27me3 circuit, the crosstalk is model-specific. This review examines these interactions in tumor cells and the immune microenvironment, emphasizing enzyme specificity, histone mark, cell type and experimental context. We highlight that changes in S-adenosylmethionine or α-KG do not produce uniform effects across enzymes, loci or cell states, and that tumor-associated macrophages are not captured by a fixed M1/M2 metabolic dichotomy. Mechanistic findings, preclinical results and early-phase clinical observations are considered separately; single-arm activity reported for valemetostat in adult T-cell leukemia/lymphoma is presented as activity in a defined cohort, not as an established survival benefit. Finally, we discuss how single-cell and spatial approaches can help resolve cell-type-specific and niche-specific interactions in heterogeneous tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.